Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioporto ASTHOXF 67 Days Sales Outstanding is 96.58 as of Jun. 2026, which is 21% above its 10-year median of 79.98. GuruFocus rates THOXF with a GF Score™ of 67/100 and a GF Value™ of $0.15. The stock has 2 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 59.2% on this metric.
Bioporto AS's average Accounts Receivable for the
six
months ended in Jun. 2026 was $1.33 Mil. Bioporto AS's Revenue for the
six
months ended in Jun. 2026 was $2.52 Mil.
Hence, Bioporto AS's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 96.58.
The historical rank and industry rank for Bioporto AS's Days Sales Outstanding or its related term are showing as below:
THOXF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.51 Med: 79.98 Max: 105.82
Current: 76.6
During the past 13 years, Bioporto AS's highest Days Sales Outstanding was 105.82. The lowest was 30.51. And the median was 79.98.
THOXF's Days Sales Outstanding is ranked worse than 59.2% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs THOXF: 76.60
Bioporto AS's Days Sales Outstanding
increased
from Jun. 2025 (72.31) to Jun. 2026 (96.58).
Bioporto AS (OTCPK:THOXF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Bioporto AS Days Sales Outstanding Related Terms
Bioporto AS Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, NTRA: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioporto AS (THOXF) has a Days Sales Outstanding of 96.58 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bioporto AS and its competitors. This is 21% above median its historical median of 79.98. Over the past decade, Bioporto AS's Days Sales Outstanding has ranged from 30.51 to 105.82. According to the industry distribution chart, Bioporto AS ranks #119 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 59.2%.
Is Bioporto AS's Days Sales Outstanding too high?
Bioporto AS's current Days Sales Outstanding of 96.58 is 21% above median its 10-year median of 79.98. Over the past 10 years, this metric has ranged from a low of 30.51 to a high of 105.82. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Bioporto AS's value of 96.58 is 42.9% above this industry median. Based on the distribution chart, Bioporto AS ranks #119 out of 201 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bioporto AS has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #119 out of 201 companies for Days Sales Outstanding. This places Bioporto AS in the lower half of its industry. The industry median Days Sales Outstanding is 67.59. Bioporto AS's value of 96.58 is 42.9% above this benchmark. Historically, Bioporto AS's own Days Sales Outstanding has ranged from 30.51 to 105.82 over the past decade. While the company's 10-year median is 79.98 vs. the industry median of 67.59, Bioporto AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Days Sales Outstanding of 96.58 is 42.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Days Sales Outstanding is 96.58, which is 21% above median its own 10-year median of 79.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Days Sales Outstanding of 96.58. The stock's GF Value™ is $0.15, compared to a current price of $0.15 — trading 0.7% below its estimated fair value. The current Days Sales Outstanding is 96.58, which is 21% above median its 10-year median of 79.98 and 42.9% above the Medical Diagnostics & Research industry median of 67.59. Bioporto AS's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Days Sales Outstanding is 96.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 0.7% below its estimated GF Value™ of $0.15.
Key valuation signals for THOXF:
Days Sales Outstanding: 96.58 (21% above median its 10-year median of 79.98)
GF Value™: $0.15 vs. price of $0.15 (0.7% below fair value)
Industry Position: 42.9% above the Medical Diagnostics & Research median (#119 of 201)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
67GF Score
Get the complete analysis for THOXF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
